NCT01616758 2024-03-08
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
GTx
Phase 2 Terminated
Clinical Trials
6 trialsNCT02746328 2024-02-26
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
GTx
Phase 2 Withdrawn
NCT05065411 2024-02-26
VERU-024
Veru Inc.
Phase 3 Terminated
NCT04869943 2024-01-26
ARTEST
Veru Inc.
Phase 3 Terminated
NCT02463032 2020-12-09
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
GTx
Phase 2 Completed
NCT02368691 2020-11-18
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
GTx
Phase 2 Terminated